TSLC1和4.1B在非小细胞肺癌中的表达及临床意义

BACKGROUND AND OBJECTIVE: Tumor suppressor in lung cancer-1 (TSLC1) belongs to immunoglobulin superfamily of cell adhesion molecule and differentially expressed in adenocarcinoma of the lung (4.1B)belongs to NF2/ERM/4.1 protein superfamily. They may suppress carcinogenesis via construction of the adjacent cell adhesion stability. The aim of this study is to detect the expressions of TSLC1 and 4.1B in non-small cell lung cancer and the clinical pathological significances. METHODS: The expressions of TSLC1 and 4.1B were detected by RT-PCR in 52 cases of non-small cell lung cancer and corresponding adjacent cancer lung tissues. RESULTS: The expressions of TSLC1 and 4.1B in cancer tissues were significantly lower than that in adjacent cancer lung tissues (0.349±0.008 vs 0.555±0.010; 0.209±0.040 vs 0.721±0.071) (P < 0.01). The expressions of TSLC1 and 4.1B showed a significant correlation with cancer differentiation and TNM staging (P < 0.05), but not with gender, age and pathological type (P > 0.05). The expressions of TSLC1 and 4.1B were positively correlated (r=0.471, P < 0.001). CONCLUSION: Down-regulated expressions of TSLC1 and 4.1B in non-small cell lung cancer, both may participate in a cascade of non-small cell lung cancer occurrence and development. TSLC1 and 4.1B are promising targets for non-small cell lung cancer diagnosis and treatment.